← Leaderboards
Edgar G. Engleman
Stanford University
$35,389,843
Attributed
$37,615,544
Total exposure
27
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,771,539 · 29
By mechanism
P01$22,593,113 · 11
R01$17,611,296 · 9
U54$9,348,723 · 3
U01$2,362,014 · 1
R21$437,968 · 1
M01$270,556 · 2
Top collaborators
- Billy W Loo7 shared
- Samuel Strober5 shared
- Sylvia Katina Plevritis3 shared
Most similar at Stanford University
Same institution · by research overlap
- Samuel Strober$36,157,957
- Robert S Negrin$29,816,136
- Judith Anne Shizuru$11,975,284
- Bryan Sun$5,464,263
- Asha Bhaskaran Pillai$2,775,962
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmuneImmune SystemT-LymphocyteMouse ModelTumorImmune ResponseMalignant NeoplasmsNeoplastic CellBaseImmunotherapyMediatingMolecularTissuesCytokineDendritic CellsCell TypeProgramsResponseAntibodiesTumor ImmunityFlow CytometryExhibitsNeoplasm Metastasis
Grant awards (124)
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic Progression$1,930,840
U54 · FY2025 · CA
Targeting Lymph Node Dependent Immune Tolerance in Cancer$546,149
R01 · FY2025 · CA · contact PI
Project 1 Mouse Models Analysis$529,826
U54 · FY2025 · CA · contact PI
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity$495,372
R01 · FY2025 · CA · contact PI
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy$430,212
P01 · FY2025 · CA · contact PI
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic Progression$1,834,299
U54 · FY2024 · CA
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity$690,624
R01 · FY2024 · CA · contact PI
Targeting Lymph Node Dependent Immune Tolerance in Cancer$514,984
R01 · FY2024 · CA · contact PI
Project 1 Mouse Models Analysis$503,335
U54 · FY2024 · CA · contact PI
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy$408,703
P01 · FY2024 · CA · contact PI
Effects of FLASH Radiation on Cancer and the Immune Response$104,503
R01 · FY2024 · CA · contact PI
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic Progression$1,919,101
U54 · FY2023 · CA
Project 1 Mouse Models Analysis$563,617
U54 · FY2023 · CA · contact PI
Targeting Lymph Node Dependent Immune Tolerance in Cancer$527,382
R01 · FY2023 · CA · contact PI
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity$485,465
R01 · FY2023 · CA · contact PI
Effects of FLASH Radiation on Cancer and the Immune Response$483,153
R01 · FY2023 · CA · contact PI
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy$421,608
P01 · FY2023 · CA · contact PI
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity$231,825
R01 · FY2023 · CA · contact PI
Targeting Lymph Node Dependent Immune Tolerance in Cancer$523,629
R01 · FY2022 · CA · contact PI
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity$485,465
R01 · FY2022 · CA · contact PI
Effects of FLASH Radiation on Cancer and the Immune Response$483,153
R01 · FY2022 · CA · contact PI
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy$421,611
P01 · FY2022 · CA · contact PI
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer$419,692
R01 · FY2022 · CA · contact PI
Effects of FLASH Radiation on Cancer and the Immune Response$105,129
R01 · FY2022 · CA · contact PI
Targeting Lymph Node Dependent Immune Tolerance in Cancer$531,707
R01 · FY2021 · CA · contact PI
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity$526,078
R01 · FY2021 · CA · contact PI
Effects of FLASH Radiation on Cancer and the Immune Response$493,013
R01 · FY2021 · CA · contact PI
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy$443,282
P01 · FY2021 · CA · contact PI
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer$434,773
R01 · FY2021 · CA · contact PI
Effects of FLASH Radiation on Cancer and the Immune Response$493,013
R01 · FY2020 · CA · contact PI
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer$434,773
R01 · FY2020 · CA · contact PI
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning$425,843
P01 · FY2020 · HL · contact PI
Project 1: Murine Modeling of Tumor-Mediated Immunosuppression$377,697
U54 · FY2020 · CA · contact PI
Scientific Core$248,163
P01 · FY2020 · HL · contact PI
Effects of Maternal Obesity on Offspring Immune System$199,003
R21 · FY2020 · HD · contact PI
Effects of FLASH Radiation on Cancer and the Immune Response$493,013
R01 · FY2019 · CA · contact PI
Project 1: Murine Modeling of Tumor-Mediated Immunosuppression$466,711
U54 · FY2019 · CA · contact PI
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning$425,843
P01 · FY2019 · HL · contact PI
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer$421,729
R01 · FY2019 · CA · contact PI
Role of Dendritic Cells in Mixed Chimerism and Tolerance$399,682
R01 · FY2019 · AI · contact PI
Scientific Core$248,163
P01 · FY2019 · HL · contact PI
Effects of Maternal Obesity on Offspring Immune System$238,965
R21 · FY2019 · HD · contact PI
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer$434,773
R01 · FY2018 · CA · contact PI
Project 1: Murine Modeling of Tumor-Mediated Immunosuppression$429,256
U54 · FY2018 · CA · contact PI
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning$420,527
P01 · FY2018 · HL · contact PI
Role of Dendritic Cells in Mixed Chimerism and Tolerance$399,400
R01 · FY2018 · AI · contact PI
Scientific Core$245,068
P01 · FY2018 · HL · contact PI
Applicability of Mouse Breast Cancer Models to Tumor-Immune Network Investigation$570,517
R01 · FY2017 · CA · contact PI
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning$418,548
P01 · FY2017 · HL · contact PI
Project 1: Murine Modeling of Tumor-Mediated Immunosuppression$401,513
U54 · FY2017 · CA · contact PI
Role of Dendritic Cells in Mixed Chimerism and Tolerance$399,135
R01 · FY2017 · AI · contact PI
Scientific Core$243,915
P01 · FY2017 · HL · contact PI
Applicability of Mouse Breast Cancer Models to Tumor-Immune Network Investigation$570,517
R01 · FY2016 · CA · contact PI
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning$471,607
P01 · FY2016 · HL · contact PI
Role of Dendritic Cells in Mixed Chimerism and Tolerance$398,884
R01 · FY2016 · AI · contact PI
Project 1: Murine Modeling of Tumor-Mediated Immunosuppression$392,528
U54 · FY2016 · CA · contact PI
Scientific Core$273,780
P01 · FY2016 · HL · contact PI
Applicability of Mouse Breast Cancer Models to Tumor-Immune Network Investigation$570,517
R01 · FY2015 · CA · contact PI
Defining Adaptive Immune Mechanisms of Insulin Resistance$364,890
R01 · FY2015 · DK · contact PI
Role of Dendritic Cells in Mixed Chimerism and Tolerance$199,324
R01 · FY2015 · AI · contact PI
Defining Adaptive Immune Mechanisms of Insulin Resistance$391,356
R01 · FY2014 · DK · contact PI
Role of Functionally Distinct Dendritic Cell Subsets in Tolerance and GVHD$274,275
P01 · FY2014 · HL · contact PI
Immune Assay, Flow Cytometry and Gene Profiling$223,248
P01 · FY2014 · HL · contact PI
Immunology$47,099
P30 · FY2014 · CA · contact PI
Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model$443,110
U01 · FY2013 · CA · contact PI
Defining Adaptive Immune Mechanisms of Insulin Resistance$375,157
R01 · FY2013 · DK · contact PI
Role of Functionally Distinct Dendritic Cell Subsets in Tolerance and GVHD$266,438
P01 · FY2013 · HL · contact PI
Immune Assay, Flow Cytometry and Gene Profiling$216,869
P01 · FY2013 · HL · contact PI
Immunology$9,682
P30 · FY2013 · CA · contact PI
Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model$473,351
U01 · FY2012 · CA · contact PI
Defining Adaptive Immune Mechanisms of Insulin Resistance$388,764
R01 · FY2012 · DK · contact PI
Role of Functionally Distinct Dendritic Cell Subsets in Tolerance and GVHD$279,872
P01 · FY2012 · HL · contact PI
Immune Assay, Flow Cytometry and Gene Profiling$227,805
P01 · FY2012 · HL · contact PI
Immunology$10,344
P30 · FY2012 · CA · contact PI
Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model$470,159
U01 · FY2011 · CA · contact PI
Role of Functionally Distinct Dendritic Cell Subsets in Tolerance and GVHD$279,872
P01 · FY2011 · HL · contact PI
Immune Assay, Flow Cytometry and Gene Profiling$227,805
P01 · FY2011 · HL · contact PI
Immunology$10,585
P30 · FY2011 · CA · contact PI
Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model$492,416
U01 · FY2010 · CA · contact PI
Role of Functionally Distinct Dendritic Cell Subsets in Tolerance and GVHD$279,872
P01 · FY2010 · HL · contact PI
Immune Assay, Flow Cytometry and Gene Profiling$227,805
P01 · FY2010 · HL · contact PI
Immunology$11,915
P30 · FY2010 · CA · contact PI
Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model$482,978
U01 · FY2009 · CA · contact PI
PROG 7- Cancer Immunology and Immunotherapy$20,909
P30 · FY2009 · CA · contact PI
LANGERHANS CELL REPLACEMENT FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION$419,983
P01 · FY2008 · HL · contact PI
IMMUNE ASSAY AND FLOW CYTOMETRY CORE$288,305
P01 · FY2008 · HL · contact PI
PROG 7- Cancer Immunology and Immunotherapy$20,369
P30 · FY2008 · CA · contact PI
LANGERHANS CELL REPLACEMENT FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION$438,636
P01 · FY2007 · HL · contact PI
Dendritic Cell-NK T Cell Interactions in the SLE$346,947
R01 · FY2007 · AR · contact PI
IMMUNE ASSAY AND FLOW CYTOMETRY CORE$297,938
P01 · FY2007 · HL · contact PI
PROG 7- Cancer Immunology and Immunotherapy$16,966
P30 · FY2007 · CA · contact PI
Novel Transfusion Based Immune Modulation$1,599,054
P01 · FY2006 · HL · contact PI
LANGERHANS CELL REPLACEMENT AFTER STEM CELL TRANSPLANT$374,398
P01 · FY2006 · HL · contact PI
Dendritic Cell-NK T Cell Interactions in the SLE$357,236
R01 · FY2006 · AR · contact PI
CORE--FLOW CYTOMETRY$327,507
P01 · FY2006 · HL · contact PI
Dendritic cell immunotherapy for colorectal cancer$327,507
P01 · FY2006 · HL · contact PI
IIMMUNE ASSAY AND FLOW CYTOMETRY CORE$253,048
P01 · FY2006 · HL · contact PI
Novel Transfusion Based Immune Modulation$1,596,422
P01 · FY2005 · HL
LANGERHANS CELL REPLACEMENT AFTER STEM CELL TRANSPLANT$366,164
P01 · FY2005 · HL
Dendritic Cell-NK T Cell Interactions in the SLE$365,763
R01 · FY2005 · AR
IIMMUNE ASSAY AND FLOW CYTOMETRY CORE$246,205
P01 · FY2005 · HL
Novel Transfusion Based Immune Modulation$1,482,923
P01 · FY2004 · HL
Dendritic Cell-NK T Cell Interactions in the SLE$365,695
R01 · FY2004 · AR
LANGERHANS CELL REPLACEMENT AFTER STEM CELL TRANSPLANT$356,065
P01 · FY2004 · HL
IIMMUNE ASSAY AND FLOW CYTOMETRY CORE$239,170
P01 · FY2004 · HL
Novel Transfusion Based Immune Modulation$1,435,895
P01 · FY2003 · HL
ROLE OF CTLA 4 IN IMMUNE TOLERANCE IN HUMANS$262,705
R01 · FY2003 · CA
Novel Transfusion Based Immune Modulation$1,394,062
P01 · FY2002 · HL
ROLE OF CTLA 4 IN IMMUNE TOLERANCE IN HUMANS$262,705
R01 · FY2002 · CA
CORE--FLOW CYTOMETRY$189,283
P01 · FY2002 · HL
Dendritic cell immunotherapy for colorectal cancer$189,283
P01 · FY2002 · HL
NOVEL TRANSFUSION BASED IMMUNE MODULATION$993,693
P01 · FY2001 · HL
ROLE OF CTLA 4 IN IMMUNE TOLERANCE IN HUMANS$262,705
R01 · FY2001 · CA
CORE--FLOW CYTOMETRY$189,283
P01 · FY2001 · HL
TRANSFUSION BASED IMMUNOTHERAPY FOR COLORECTAL CANCER$189,283
P01 · FY2001 · HL
DENDRITIC CELL THERAPY FOR PROSTATE CANCER$134,676
M01 · FY2001 · RR
PHASE I OF FLT3L MOBILIZED DENDRITIC CELL FOR LUNG &COLON CANCER$134,676
M01 · FY2001 · RR
DENDRITIC CELL THERAPY FOR PROSTATE CANCER$0
M01 · FY2001 · RR
PHASE I OF FLT3L MOBILIZED DENDRITIC CELL FOR LUNG &COLON CANCER$0
M01 · FY2001 · RR
NOVEL TRANSFUSION BASED IMMUNE MODULATION$969,706
P01 · FY2000 · HL
CORE--FLOW CYTOMETRY$189,283
P01 · FY2000 · HL
TRANSFUSION BASED IMMUNOTHERAPY FOR COLORECTAL CANCER$189,283
P01 · FY2000 · HL
PHASE I OF FLT3L MOBILIZED DENDRITIC CELL FOR LUNG &COLON CANCER$602
M01 · FY2000 · RR
DENDRITIC CELL THERAPY FOR PROSTATE CANCER$602
M01 · FY2000 · RR